Tyra Biosciences (NASDAQ:TYRA – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07), FiscalAI reports.
Tyra Biosciences Stock Performance
Shares of Tyra Biosciences stock traded down $0.60 during trading on Tuesday, hitting $21.70. 105,705 shares of the company’s stock were exchanged, compared to its average volume of 889,703. Tyra Biosciences has a 52-week low of $13.83 and a 52-week high of $40.65. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -9.05 and a beta of 0.65. The business has a 50-day simple moving average of $22.12 and a 200-day simple moving average of $29.59.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on TYRA shares. Wedbush reiterated an “outperform” rating and issued a $53.00 price target on shares of Tyra Biosciences in a research report on Thursday, September 10th. Piper Sandler reiterated an “overweight” rating and set a $56.00 target price on shares of Tyra Biosciences in a research report on Tuesday, September 8th. HC Wainwright decreased their price objective on Tyra Biosciences from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, September 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Tyra Biosciences in a research report on Thursday, September 10th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $40.00 target price (down from $50.00) on shares of Tyra Biosciences in a research report on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.20.
View Our Latest Report on TYRA
Tyra Biosciences Company Profile
Tyra Biosciences, Inc is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges.
The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.
See Also
- Five stocks we like better than Tyra Biosciences
- Barrick’s Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
